Location: Home > About Us

About Aim Pharm

Founded in 2003, Tibet Aim Pharmaceuticals Techonology Ltd. (Hereinafter refered to as Aim Pharm) is a national Hi-Tech comprehensive medicine enterprise that has its own herb planting base, research and develop center for Chinese traditional medicine (crude drug and inhibitor), manufacturing factory and retailing channel all over China.

A series of our products such as Miglitol Tablets, Gualoupi Injection, Nalmefene HydrochlorideInjection, Carbetocin Injection; Hongjin Xiaojie Tablets and Aceclofenac Enteric-Coated Tablets have been catalogued into the National Medical Insurance Registeration. We have also expanded our products for antibiotic treatment, antiallergic and digestic system. 

Act in accordance with "Simple and Practical, Innovation for All", employees with Aim Pharm are performance-oriented and motivated by research and developement initiatives. Thanks to that, now we own quite a few patents in First Generic Drugs, a few other patented prizes, new drug certificates and pharmaceutical production approvals in China domestic market.

Motivated by that great company culture, we are recogonized and prized by quite a few hornors, such as "Tibetan Small and Midlle Sized Technology Company", "National New Hi-Tech Enterprise", "National Technology Incubator", "National Science and Technology Incubator", "Council Member of National Cardiocerebral and Vascular Disease Prevention Center", "China Excellent Patent Prize", "Grade A Tax Payer Credit Enterprise". Our subsidiary Sichuan Weiao has also won a series of recognition by local government, such as "New Hi-tech Enterprise","Chengdu New Hi-tech Enterprise", "Chengdu Top 50 Industrial Businiess", "Chengdu Critical Advantage Enterprise", "Chengdu Leading Tax Payer Enterprise", "Chengdu Tax Payer Model Enterprise", business bank AAA credit certificate. 

Benifited by the exclusive biological resources in Tibet and preferential policy from state government, EMYY has experienced rapid growth and is now a listed company in Shenzhen Stock Exchange Market since Dec 9th, 2016. 

In future, the company will utilize its competence in core products, analyze the pharmaceutical market from every aspect and work on every challenge and seize every opportunity to grow in accordance with government reform of the medical system. We are also committed to build an excellent human resource management system, a comprehensive accounting system, an effecient business system to access to the capital market. We always serve to people's health, help people cure their disease. With our high quality, best value products and the core competitiveness, we will not only build an excellent organization that takes its social responsibility but also become a China leading pharmaceutical company fighting against chronic disease.